Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:26 15/05/2026 BST			5-day change	1st Jan Change
13,632.00 ^GBX	-0.79%		+2.16%	-1.15%

05-14	AstraZeneca bladder cancer trial yields encouraging results	AN
05-14	European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading	MT

Press Releases

05-14	Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial	BU
05-14	AstraZeneca : Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial	PU
05-12	AstraZeneca : Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial	PU
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
05-03	AstraZeneca invests £300 million in UK drug development sites	AQ
05-01	TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
05-01	AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
04-30	AstraZeneca : Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer	PU
04-30	Astrazeneca injects £300m into UK sites	AQ
04-30	Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca	PR
04-29	Astrazeneca tops expectations in the first quarter on strong cancer drug sales	AQ
04-29	AstraZeneca results: Q1 2026	BU
04-29	AstraZeneca : Q1 2026 results clinical trials appendix (Q1 2026 results clinical trials appendix)	PU
04-29	Astrazeneca: Q1 Earnings Snapshot	AQ
04-28	BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older	BU
04-27	SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus	BU
04-20	Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD	BU
04-20	AstraZeneca : Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD	PU
04-09	AstraZeneca : Special Business Approved at AGM	PU
04-09	AstraZeneca : Results of Annual General Meeting held on 9 April 2026 (Results of Annual General Meeting held on 9 April 2026)	PU
04-08	AstraZeneca : Sustainability Data Reporting Criteria 2025	PU
04-08	AstraZeneca : Assurance Report for Sustainability Data Annex 2025	PU